Science Corp. secured $230 million in Series C funding to accelerate the commercialization of its PRIMA retinal implant and expand its biohybrid neural research. This capital injection brings the neurotech startup’s total funding to $490 million as it scales operations to address severe vision loss and advanced brain-computer interfacing.
Commercializing Vision Restoration Technology
The primary focus of this investment involves the PRIMA clinical trial program. Science Corp. is currently expanding these trials to include patients suffering from Stargardt disease and retinitis pigmentosa. These inherited retinal conditions remain the leading causes of vision impairment in young adults, and the PRIMA device aims to restore functional sight by bypassing damaged photoreceptors.
Advancing Biohybrid Neural Interfaces
Beyond its immediate clinical goals, the company is funneling resources into a high-tech biohybrid neural interface program. This project involves cultivating engineered neurons derived from stem cells onto a specialized, waffle-like substrate. When placed on the brain’s surface, this device facilitates direct biological connections with existing neural circuits, potentially enabling more seamless integration between digital hardware and organic tissue.
Redefining Organ Longevity with Vessel
The startup also introduced Vessel, a new business unit dedicated to organ preservation. Vessel utilizes miniaturized perfusion technology to maintain organ health outside of traditional hospital settings. This innovation seeks to enable organ transport via commercial flights or allow patients to maintain organs at home, significantly reducing the reliance on intensive care units for transplant logistics.
Strategic Investment and Institutional Backing
The Series C round attracted a diverse group of elite investors, including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, and Quiet Capital. Notably, IQT—the venture capital firm that identifies technology solutions for the CIA and FBI—also participated in the round. Science Corp. currently maintains a workforce of 150 employees as it transitions from research-heavy operations to commercial viability.
